0
0
11/5/22 at 2:36pm
Organization
Hcplive.com
Author
Kenny Walter
31 words
0
Comments
In a late-breaking abstract presented at ASN 2022, dapagliflozin attenuated the decline in eGFR between month 1-36 compared to placebo.
You are the first to view
https://www.hcplive.com/view/dapagliflozin-slows-rate-kidney-decline
Create an account
or login to join the discussion